{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:54:28Z","timestamp":1790420068812,"version":"4.1.0"},"reference-count":76,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hereditary transthyretin amyloidosis (ATTRv) is a rare autosomal dominant adult-onset disorder caused by point mutations in the transthyretin (TTR) gene encoding TTR, also known as prealbumin. ATTRv survival ranges from 3 to 10 years, and peripheral nervous system and heart are usually the 2 main tissues affected, although central nervous system and eye may also be involved. Because the liver is the main TTR protein secretor organ, it has been the main target of treatments developed these last years, including liver transplantation, which has been shown to significantly increase survival in a subset of patients carrying the so-called \u201cearly-onset Val30Met\u201d TTR gene mutation. More recently, treatments targeting hepatic TTR RNA have been developed. Hepatic TTR RNA targeting is performed using RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies involving lipid nanoparticle carriers or N-acetylgalactosamine fragments. RNAi and ASO treatments induce an 80% decrease in TTR liver production for a period of 1 to 12 weeks. ASO and RNAi phase 3 trials in patients with TTR-related polyneuropathy have shown a positive impact on neuropathy clinical scores and quality of life end points, and delayed RNAi treatment negatively affects survival. Clinical trials specifically investigating RNAi therapy in TTR cardiomyopathy are underway. Hepatic RNA targeting has revolutionized ATTRv treatment and may allow for the transforming a fatal disease into a treatable disorder. Because retina and choroid plexus secrete limited quantities of TTR protein, both tissues are now seen as the next targets for fully controlling the disease.<\/jats:p>","DOI":"10.1182\/blood.2023019884","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T17:54:50Z","timestamp":1692986090000},"page":"1600-1612","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-4108","authenticated-orcid":false,"given":"David","family":"Adams","sequence":"first","affiliation":[{"name":"1Neurology Department, Bic\u00eatre Hospital, INSERM U 1195, CERAMIC, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris Saclay, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-1235","authenticated-orcid":false,"given":"Vincent","family":"Algalarrondo","sequence":"additional","affiliation":[{"name":"2Cardiology Department, CERAMIC, Bichat Claude Bernard Hospital, University of Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andoni","family":"Echaniz-Laguna","sequence":"additional","affiliation":[{"name":"1Neurology Department, Bic\u00eatre Hospital, INSERM U 1195, CERAMIC, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris Saclay, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2023110916245186700_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"2023110916245186700_bib2","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"2023110916245186700_bib3","doi-asserted-by":"crossref","first-page":"e003352","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2023110916245186700_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"issue":"2","key":"2023110916245186700_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2023110916245186700_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/NRL.0000000000000337","article-title":"Current review of leptomeningeal amyloidosis associated with transthyretin mutations","volume":"26","author":"Qin","year":"2021","journal-title":"Neurologist"},{"key":"2023110916245186700_bib7","doi-asserted-by":"crossref","first-page":"821003","DOI":"10.3389\/fneur.2021.821003","article-title":"TTR Gly83Arg mutation: beyond familial vitreous amyloidosis","volume":"12","author":"Li","year":"2021","journal-title":"Front Neurol"},{"issue":"9","key":"2023110916245186700_bib8","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"issue":"5","key":"2023110916245186700_bib9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/ene.15268","article-title":"Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis","volume":"29","author":"Leonardi","year":"2022","journal-title":"Eur J Neurol"},{"issue":"24","key":"2023110916245186700_bib10","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"2023110916245186700_bib11","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"12","key":"2023110916245186700_bib12","doi-asserted-by":"crossref","first-page":"e126526","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"2023110916245186700_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023110916245186700_bib14","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"2023110916245186700_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"2023110916245186700_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 1","key":"2023110916245186700_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/13506129.2011.574354059","article-title":"Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy","volume":"18","author":"Connors","year":"2011","journal-title":"Amyloid"},{"issue":"11","key":"2023110916245186700_bib18","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch Neurol"},{"issue":"5","key":"2023110916245186700_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese","year":"2017","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2023110916245186700_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"2023110916245186700_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve"},{"issue":"6","key":"2023110916245186700_bib22","first-page":"2109","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"2023110916245186700_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"issue":"21","key":"2023110916245186700_bib24","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"2023110916245186700_bib25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Writing","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2023110916245186700_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2023110916245186700_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2023110916245186700_bib28","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1038\/s41598-021-91113-6","article-title":"Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry","volume":"11","author":"Parker","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"2023110916245186700_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"2023110916245186700_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13506129.2018.1550061","article-title":"Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy","volume":"25","author":"Algalarrondo","year":"2018","journal-title":"Amyloid"},{"issue":"22","key":"2023110916245186700_bib31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"2023110916245186700_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"27","key":"2023110916245186700_bib33","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"issue":"19","key":"2023110916245186700_bib34","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.jacc.2015.08.870","article-title":"Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis","volume":"66","author":"Algalarrondo","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"2023110916245186700_bib35","first-page":"1432","article-title":"Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation","volume":"9","author":"Algalarrondo","year":"2016","journal-title":"JACC\u00a0Cardiovasc Imaging"},{"issue":"24","key":"2023110916245186700_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","article-title":"CNS involvement in hereditary transthyretin amyloidosis","volume":"97","author":"Sousa","year":"2021","journal-title":"Neurology"},{"key":"2023110916245186700_bib37","first-page":"109","article-title":"Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis","volume":"30(1)","author":"Takahashi","year":"2022","journal-title":"Amyloid"},{"key":"2023110916245186700_bib38","doi-asserted-by":"crossref","first-page":"816636","DOI":"10.3389\/fneur.2022.816636","article-title":"Cerebellar and cerebral amyloid visualized by [(18)f]flutemetamol pet in long-term hereditary V30M (p.V50M) transthyretin amyloidosis survivors","volume":"13","author":"Uneus","year":"2022","journal-title":"Front Neurol"},{"issue":"3","key":"2023110916245186700_bib39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin Genet"},{"issue":"pt 7","key":"2023110916245186700_bib40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"Adams","year":"2000","journal-title":"Brain"},{"issue":"4","key":"2023110916245186700_bib41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"2023110916245186700_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"2023110916245186700_bib43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"issue":"5","key":"2023110916245186700_bib44","first-page":"916","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"2023110916245186700_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023110916245186700_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110916245186700_bib47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"issue":"1","key":"2023110916245186700_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023110916245186700_bib49","doi-asserted-by":"crossref","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS\u00a0+ 7","volume":"405","author":"Dyck","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"issue":"7","key":"2023110916245186700_bib50","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/ene.15325","article-title":"Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: data from an early-access program in Italy","volume":"29","author":"Luigetti","year":"2022","journal-title":"Eur J Neurol"},{"issue":"1","key":"2023110916245186700_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/nat.2019.0796","article-title":"Nonclinical safety profile of revusiran, a 1st-generation GalNAc-siRNA conjugate for treatment of\u00a0hereditary transthyretin-mediated amyloidosis","volume":"30","author":"Sutherland","year":"2020","journal-title":"Nucleic Acid Ther"},{"issue":"2","key":"2023110916245186700_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2023110916245186700_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"21","key":"2023110916245186700_bib54","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2023110916245186700_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"2023110916245186700_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"2023110916245186700_bib57","first-page":"6416","article-title":"Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update","volume":"269","author":"Brannagan","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"2023110916245186700_bib58","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"issue":"4","key":"2023110916245186700_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid"},{"issue":"2","key":"2023110916245186700_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1814074","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy","volume":"380","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110916245186700_bib61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"2023110916245186700_bib62","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2023110916245186700_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"2023110916245186700_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"2023110916245186700_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"2023110916245186700_bib66","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1111\/bcp.15468","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis","volume":"88","author":"Diep","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2023110916245186700_bib67","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary n-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"2023110916245186700_bib68","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2023110916245186700_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"issue":"6","key":"2023110916245186700_bib70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023110916245186700_bib71","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A\u00a0human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2023110916245186700_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2023110916245186700_bib73","doi-asserted-by":"crossref","first-page":"109163","DOI":"10.1016\/j.exer.2022.109163","article-title":"Transthyretin proteoforms of intraocular origin in human subretinal fluid","volume":"222","author":"Chen","year":"2022","journal-title":"Exp Eye Res"},{"issue":"2","key":"2023110916245186700_bib74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2010.483121","article-title":"Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment","volume":"17","author":"Benson","year":"2010","journal-title":"Amyloid"},{"issue":"4","key":"2023110916245186700_bib75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2016.1256282","article-title":"Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model","volume":"23","author":"Goncalves","year":"2016","journal-title":"Amyloid"},{"issue":"3","key":"2023110916245186700_bib76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/19\/1600\/2088475\/blood_bld-2023-019884-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/19\/1600\/2088475\/blood_bld-2023-019884-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:26:02Z","timestamp":1699547162000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/19\/1600\/497632\/Hereditary-transthyretin-amyloidosis-in-the-era-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":76,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023019884","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}